Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2018-04-25
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of dasatinib when given together
with cytarabine and idarubicin hydrochloride and to see how well they work in treating
patients with acute myeloid leukemia that is likely to come back or spread. Dasatinib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs
used in chemotherapy, such as cytarabine and idarubicin hydrochloride, work in different ways
to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving dasatinib together with cytarabine and idarubicin hydrochloride may be a
better treatment for acute myeloid leukemia.